Phase I trial of a glypican-3–derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival
Y Sawada, T Yoshikawa, D Nobuoka, H Shirakawa… - Clinical Cancer …, 2012 - AACR
Purpose: The carcinoembryonic antigen glypican-3 (GPC3) is an ideal target of anticancer
immunotherapy against hepatocellular carcinoma (HCC). In this nonrandomized, open-label, …
immunotherapy against hepatocellular carcinoma (HCC). In this nonrandomized, open-label, …
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Y Sawada, T Yoshikawa, K Ofuji, M Yoshimura… - …, 2016 - Taylor & Francis
The recurrence rates of Hepatocellular carcinoma (HCC) are high, necessitating novel and
effective adjuvant therapies. Therefore, we conducted a phase II study of glypican-3 (GPC3) …
effective adjuvant therapies. Therefore, we conducted a phase II study of glypican-3 (GPC3) …
[PDF][PDF] Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy
A Minagawa, T Yoshikawa, M Yasukawa, A Hotta… - Cell Stem Cell, 2018 - cell.com
Limited T cell availability and proliferative exhaustion present major barriers to successful T
cell-based immunotherapies and may potentially be overcome through the use of "…
cell-based immunotherapies and may potentially be overcome through the use of "…
[HTML][HTML] Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer
M Oka, L Xu, T Suzuki, T Yoshikawa, H Sakamoto… - Genome biology, 2021 - Springer
Background Long-read sequencing of full-length cDNAs enables the detection of structures
of aberrant splicing isoforms in cancer cells. These isoforms are occasionally translated, …
of aberrant splicing isoforms in cancer cells. These isoforms are occasionally translated, …
[HTML][HTML] Next-generation cancer immunotherapy targeting glypican-3
Y Shimizu, T Suzuki, T Yoshikawa, I Endo… - Frontiers in …, 2019 - frontiersin.org
Glypican-3 (GPC3), a 65 kD protein consisting of 580 amino acids, is a heparan sulfate
proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is …
proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is …
Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy
T Yoshikawa, Z Wu, S Inoue, H Kasuya… - Blood, The Journal …, 2022 - ashpublications.org
Adoptive cancer immunotherapy can induce objective clinical efficacy in patients with
advanced cancer; however, a sustained response is achieved in a minority of cases. The …
advanced cancer; however, a sustained response is achieved in a minority of cases. The …
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes
…, H Shirakawa, T Yoshikawa… - International …, 2012 - spandidos-publications.com
Glypican-3 (GPC3), a carcinoembryonic antigen, is an ideal target for anticancer immunotherapy
against hepatocellular carcinoma (HCC). In this study, we attempted to compare the …
against hepatocellular carcinoma (HCC). In this study, we attempted to compare the …
[HTML][HTML] Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
YU Sawada, T Yoshikawa… - International …, 2015 - spandidos-publications.com
Novel treatment modalities are required urgently in patients with hepatocellular carcinoma (HCC).
A vaccine that induces cytotoxic T lymphocytes (CTLs) is an ideal strategy for cancer, …
A vaccine that induces cytotoxic T lymphocytes (CTLs) is an ideal strategy for cancer, …
HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells
T Yoshikawa, M Nakatsugawa, S Suzuki… - Cancer …, 2011 - Wiley Online Library
Glypican‐3 (GPC3) is an onco‐fetal antigen that is overexpressed in human hepatocellular
carcinoma (HCC), and is only expressed in the placenta and embryonic liver among normal …
carcinoma (HCC), and is only expressed in the placenta and embryonic liver among normal …
Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
N Tsuchiya, T Yoshikawa, N Fujinami, K Saito… - …, 2017 - Taylor & Francis
We have previously conducted a phase I trial to test the efficacy of a glypican-3 (GPC3)
peptide vaccine in patients with advanced hepatocellular carcinoma (HCC); however, its …
peptide vaccine in patients with advanced hepatocellular carcinoma (HCC); however, its …